Side-by-side · Research reference
CagrilintidevsVIP
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED35/64 cited
BPhase 3HUMAN-REVIEWED9/42 cited
VIP
Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)
IV infusion · Inhaled (investigational)Brown 2023Boesing 2022
01Mechanism of Action
Parameter
Cagrilintide
VIP
Primary target
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025
Pathway
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection
Downstream effect
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration
Feedback intact?
Yes — acts via physiological amylin pathways
Yes — exogenous VIP acts as physiological agonist
Origin
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP
Antibody development
—
—
02Dosage Protocols
Parameter
Cagrilintide
VIP
Standard dose (combination)
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
—
Monotherapy dosing
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
—
Evidence basis
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
Phase 3 RCT (TESICO)Brown 2023
816-patient randomized controlled trial in COVID-19 ARDS.
Intravenous (ARDS protocol)
—
60–90 mcg/kg/day via continuous infusion
TESICO trial protocol for COVID-19 ARDS.
Inhaled (investigational)
—
Variable dosing under clinical trial protocolsBoesing 2022
Delivered via nebulizer for direct pulmonary deposition.
Treatment duration
—
3–14 days (acute ARDS)
Reconstitution
—
Lyophilized powder reconstituted with sterile diluent per protocol
Half-life
—
~2 minutes (plasma)
Rapid clearance necessitates continuous infusion.
03Metabolic / Fat Loss Evidence
Parameter
Cagrilintide
VIP
Weight loss vs semaglutide
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
—
Absolute weight change
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
—
Glycemic benefit
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
—
Body composition
Predominant fat loss with weight reduction
—
Mitochondrial function
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
—
Key publications
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
—
04Side Effects & Safety
Parameter
Cagrilintide
VIP
Gastrointestinal
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
—
Injection site reactions
Local reactions possible with subcutaneous administration
—
Safety profile
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
—
Tolerability
Tolerability considerations similar to GLP-1RAs
—
Muscle preservation
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
—
Hypotension
—
Transient vasodilation-related blood pressure drop
Tachycardia
—
Reflex tachycardia secondary to vasodilation
Infusion site reactions
—
Erythema, phlebitis (IV administration)
GI symptoms
—
Nausea, diarrhea (VIP is endogenous GI peptide)
Overall tolerability
—
Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo
Absolute Contraindications
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
VIP
- ·Known hypersensitivity to aviptadil or formulation components
Relative Contraindications
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
VIP
- ·Severe hypotension or shock states (monitor blood pressure)
- ·Pregnancy — insufficient safety data
05Administration Protocol
Parameter
Cagrilintide
VIP
1. Dosing frequency
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.
2. Combination form
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).
3. Injection site
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.
4. Storage
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.
5. Dietary considerations
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.
06Stack Synergy
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation
VIP
— no documented stacks